The effect of cyclosporine A on the phosphorylation of the AMPK pathway in the rat hippocampus

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 8, 2011, Pages 1933-1937

  Park, Hong Geun ^a,b   Yi, Heesun ^a,b   Kim, Se Hyun ^b   Yu, Hyun Sook ^a,b   Ahn, Yong Min ^a,b   Lee, Young Han ^c   Roh, Myoung Sun ^a,b   Kim, Yong Sik ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Konkuk University   (South Korea)

Author keywords

AMP activated protein kinase; Cyclosporine A; Lipid metabolism; Phosphorylation; Rat brain

Indexed keywords

ADENOSINE PHOSPHATE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE IV; CYCLOSPORIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIVER KINASE B 1; PHOSPHOPROTEIN PHOSPHATASE 2; PHOSPHOTRANSFERASE; PROTEIN PHOSPHATASE 2C ALPHA; UNCLASSIFIED DRUG;

AMINO ACID COMPOSITION; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; HIPPOCAMPUS; MALE; NONHUMAN; RAT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CYCLOSPORINE; ENZYME INHIBITORS; HIPPOCAMPUS; LIPID METABOLISM; MALE; MAP KINASE KINASE KINASES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 82455171842     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.09.008     Document Type: Article

References (43)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
2. Carling D. The AMP-activated protein kinase cascade - a unifying system for energy control. Trends Biochem Sci 2004, 29:18-24.
3. Casey D.E. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry 2004, 65(Suppl. 18):27-35.
4. Chi Y., Li K., Yan Q., Schuichi K., Shi L., Takahashi S., et al. Nonsteroidal anti-inflammatory drug flufenamic acid is a potent activator of AMPK. J Pharmacol Exp Ther 2011, 339:257-266.
5. Coccurello R., Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther 2010, 127:210-251.
6. Fisslthaler B., Fleming I., Keseru B., Walsh K., Busse R. Fluid shear stress and NO decrease the activity of the hydroxy-methylglutaryl coenzyme A reductase in endothelial cells via the AMP-activated protein kinase and FoxO1. Circ Res 2007, 100:e12-e21.
7. Gaussin V., Hue L., Stalmans W., Bollen M. Activation of hepatic acetyl-CoA carboxylase by glutamate and Mg2+ is mediated by protein phosphatase-2A. Biochem J 1996, 316(Pt 1):217-224.
8. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
9. Hardie D.G., Scott J.W., Pan D.A., Hudson E.R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 2003, 546:113-120.
10. Hawley S.A., Boudeau J., Reid J.L., Mustard K.J., Udd L., Makela T.P., et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003, 2:28.
11. Henderson D.C., Daley T.B., Kunkel L., Rodrigues-Scott M., Koul P., Hayden D. Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry 2004, 65:686-689.
12. Herrmann J.L., Byekova Y., Elmets C.A., Athar M. Liver kinase B1 (LKB1) in the pathogenesis of epithelial cancers. Cancer Lett 2011, 306:1-9.
13. Holdaas H., Fellstrom B., Jardine A.G., Holme I., Nyberg G., Fauchald P., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003, 361:2024-2031.
14. Hurley R.L., Barre L.K., Wood S.D., Anderson K.A., Kemp B.E., Means A.R., et al. Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. J Biol Chem 2006, 281:36662-36672.
15. Jardine A.G., Holdaas H., Fellstrom B., Cole E., Nyberg G., Gronhagen-Riska C., et al. fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am J Transplant 2004, 4:988-995.
16. Kahn B.B., Alquier T., Carling D., Hardie D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005, 1:15-25.
17. Kim E.K., Park J.M., Lim S., Choi J.W., Kim H.S., Seok H., et al. Activation of AMP-activated protein kinase is essential for lysophosphatidic acid-induced cell migration in ovarian cancer cells. J Biol Chem 2011, 286:24036-24045.
18. Kim M.K., Kim S.H., Yu H.S., Park H.G., Kang U.G., Ahn Y.M., et al. The effect of clozapine on the AMPK-ACC-CPT1 pathway in the rat frontal cortex. Int J Neuropsychopharmacol 2011, 1-11.
19. Kockx M., Jessup W., Kritharides L. Cyclosporin A and atherosclerosis - cellular pathways in atherogenesis. Pharmacol Ther 2010, 128:106-118.
20. Li C., Keaney J.F. AMP-activated protein kinase: a stress-responsive kinase with implications for cardiovascular disease. Curr Opin Pharmacol 2010, 10:111-115.
21. Lodge D.J., Grace A.A. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci 2007, 27:11424-11430.
22. Long Y.C., Zierath J.R. Influence of AMP-activated protein kinase and calcineurin on metabolic networks in skeletal muscle. Am J Physiol Endocrinol Metab 2008, 295:E545-E552.
23. Lu J., Wu D.M., Zheng Y.L., Hu B., Zhang Z.F., Shan Q., et al. Quercetin activates AMP-activated protein kinase by reducing PP2C expression protecting old mouse brain against high cholesterol-induced neurotoxicity. J Pathol 2010, 222:199-212.
24. Mantovani J., Roy R. Re-evaluating the general(ized) roles of AMPK in cellular metabolism. FEBS Lett 2011, 585:967-972.
25. Martinez de Morentin P.B., Gonzalez C.R., Lopez M. AMP-activated protein kinase: 'a cup of tea' against cholesterol-induced neurotoxicity. J Pathol 2010, 222:329-334.
26. Meyer J.M., Koro C.E. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004, 70:1-17.
27. Pallottini V., Marino M., Ascenzi P. Clonidine displacement from type 1 imidazoline receptor by p-aminobenzamidine, the prototype of trypsin-like serine protease inhibitors. IUBMB Life 2002, 54:301-304.
28. Pallottini V., Martini C., Cavallini G., Bergamini E., Mustard K.J., Hardie D.G., et al. Age-related HMG-CoA reductase deregulation depends on ROS-induced p38 activation. Mech Ageing Dev 2007, 128:688-695.
29. Poels J., Spasic M.R., Callaerts P., Norga K.K. Expanding roles for AMP-activated protein kinase in neuronal survival and autophagy. Bioessays 2009, 31:944-952.
30. Ronnett G.V., Kleman A.M., Kim E.K., Landree L.E., Tu Y. Fatty acid metabolism, the central nervous system, and feeding. Obesity (Silver Spring) 2006, 14(Suppl. 5):201S-207S.
31. Ronnett G.V., Ramamurthy S., Kleman A.M., Landree L.E., Aja S. AMPK in the brain: its roles in energy balance and neuroprotection. J Neurochem 2009, 109:17-23.
32. Sanders M.J., Grondin P.O., Hegarty B.D., Snowden M.A., Carling D. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J 2007, 403:139-148.
33. Sapkota G.P., Kieloch A., Lizcano J.M., Lain S., Arthur J.S., Williams M.R., et al. Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/STK11, at Ser431 by p90(RSK) and cAMP-dependent protein kinase, but not its farnesylation at Cys(433), is essential for LKB1 to suppress cell vrowth. J Biol Chem 2001, 276:19469-19482.
34. Sato Y., Takayanagi Y., Onaka T., Kobayashi E. Impact of cyclosporine upon emotional and social behavior in mice. Transplantation 2007, 83:1365-1370.
35. Shenolikar S. Protein serine/threonine phosphatases - new avenues for cell regulation. Annu Rev Cell Biol 1994, 10:55-86.
36. Shibasaki F., Hallin U., Uchino H. Calcineurin as a multifunctional regulator. J Biochem 2002, 131:1-15.
37. 2+/Calmodulin-dependent protein kinases. Cell Mol Life Sci 2008, 65:2637-2657.
38. Szabo S.T., Machado-Vieira R., Yuan P., Wang Y., Wei Y., Falke C., et al. Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. Neuropharmacology 2009, 56:47-55.
39. Takahashi H.K., Iwagaki H., Yagi T., Kanke T., Liu K., Yoshino T., et al. Action profiles of statins and calcineurin inhibitors during human mixed lymphocyte reaction. Clin Immunol 2007, 123:324-332.
40. 2+/calmodulin-dependent protein kinase kinase-β acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2005, 2:21-33.
41. Wu Y., Song P., Xu J., Zhang M., Zou M.H. Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase. J Biol Chem 2007, 282:9777-9788.
42. Xu J., Walsh S.B., Verney Z.M., Kopelovich L., Elmets C.A., Athar M. Procarcinogenic effects of cyclosporine A are mediated through the activation of TAK1/TAB1 signaling pathway. Biochem Biophys Res Commun 2011, 408:363-368.
43. Yi H., Kim S.H., Park H.G., Yu H.S., Kim Y.S. The effect of systemic injection of cyclosporin A on the phosphorylation of the PKC substrates MARCKS and GAP43 in the rat hippocampus. Neurosci Lett 2011, 497:17-21.